|Podcasts|September 28, 2018

Episode 17: Commercializing Research

On Target Laboratories, CEO and Co-Founder, Martin R. Low and Philip S. Low, whose work the company is based off of and is also a co-founder of the company, join Christen Harm and Michelle Maskaly to talk about the ups and downs of commercializing research that has been previously shelved. They share how they approached another company to license the technology, why being persistent is a good thing if you truly believe the research can make a difference in the lives of patients and talk about what it’s been like to work with each other in a business, given that they Pharm Exec’s Editor-in-Chief Lisa Henderson and European Editor Julian Upton join Christen Harm and Michelle Maskaly to talk about the topic of specialty pharma, which was featured in the magazine’s September issue. They discuss the marketing, logistics, pricing, and other challenges executives in the specialty pharma industry face, as well as dive into the forces that are driving this segment of the industry and what the future will look like.

On Target Laboratories, CEO and Co-Founder, Martin R. Low and Philip S. Low, whose work the company is based off of and is also a co-founder of the company, join Christen Harm and Michelle Maskaly to talk about the ups and downs of commercializing research that has been previously shelved. They share how they approached another company to license the technology, why being persistent is a good thing if you truly believe the research can make a difference in the lives of patients and talk about what it’s been like to work with each other in a business, given that they are brothers. Martin R. Low also discusses what it’s been like for him to run a pharma company, since his prior expertise ranges a variety of other industries outside of pharma.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.

 


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
Pharmaceutical Executive daily
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.